There are also case reports of the pediatric population benefiting with dabrafenib plus trametinib in the treatment of BRAF mutation-positive glioblastoma and gliomas32–34, pancreatic acinar cell carcinoma35 and Wilms tumor36. Here, BRAF is linked to glioblastoma.